Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Biotransformation of nevirapine, a non-nucleoside HIV-1 reverse transcriptase inhibitor, in mice, rats, rabbits, dogs, monkeys, and chimpanzees.

Riska PS, Joseph DP, Dinallo RM, Davidson WC, Keirns JJ, Hattox SE.

Drug Metab Dispos. 1999 Dec;27(12):1434-47.

PMID:
10570025
2.

Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 8. 8-Aryloxymethyl- and 8-arylthiomethyldipyridodiazepinones.

Cywin CL, Klunder JM, Hoermann M, Brickwood JR, David E, Grob PM, Schwartz R, Pauletti D, Barringer KJ, Shih CK, Sorge CL, Erickson DA, Joseph DP, Hattox SE.

J Med Chem. 1998 Jul 30;41(16):2972-84.

PMID:
9685236
3.

Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 7. 8-Arylethyldipyridodiazepinones as potent broad-spectrum inhibitors of wild-type and mutant enzymes.

Klunder JM, Hoermann M, Cywin CL, David E, Brickwood JR, Schwartz R, Barringer KJ, Pauletti D, Shih CK, Erickson DA, Sorge CL, Joseph DP, Hattox SE, Adams J, Grob PM.

J Med Chem. 1998 Jul 30;41(16):2960-71.

PMID:
9685235
4.

Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus.

Cheeseman SH, Havlir D, McLaughlin MM, Greenough TC, Sullivan JL, Hall D, Hattox SE, Spector SA, Stein DS, Myers M, et al.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Feb 1;8(2):141-51.

PMID:
7530585
5.

A prodrug of a 2,6-disubstituted 4-(2-arylethenyl)phenol is a selective and orally active 5-lipoxygenase inhibitor.

Farina PR, Graham AG, Homon CA, Lazer ES, Hattox SE, Riska PS, Gundel RH, Wegner CD.

J Pharmacol Exp Ther. 1993 May;265(2):483-9.

PMID:
8388452
6.

Pharmacokinetics of nevirapine: initial single-rising-dose study in humans.

Cheeseman SH, Hattox SE, McLaughlin MM, Koup RA, Andrews C, Bova CA, Pav JW, Roy T, Sullivan JL, Keirns JJ.

Antimicrob Agents Chemother. 1993 Feb;37(2):178-82.

7.

Plasma free MHPG and neuroendocrine responses to challenge doses of clonidine in Tourette's syndrome: preliminary report.

Young JG, Cohen DJ, Hattox SE, Kavanagh ME, Anderson GM, Shaywitz BA, Maas JW.

Life Sci. 1981 Oct 5;29(14):1467-75. No abstract available.

PMID:
6946271
8.

Catecholamine metabolites in human plasma as indices of brain function: effects of debrisoquin.

Swann AC, Maas JW, Hattox SE, Landis H.

Life Sci. 1980 Nov 17;27(20):1857-62. No abstract available.

PMID:
7193269
9.

Estimates of dopamine and serotonin synthesis by the awake human brain.

Maas JW, Hattox SE, Greene NM, Landis DH.

J Neurochem. 1980 Jun;34(6):1547-9. No abstract available.

PMID:
6155442
10.

Variance in the production of homovanillic acid and 3-methoxy-4-hydroxyphenethyleneglycol by the awake primate brain.

Maas JW, Hattox SE, Landis DH.

Life Sci. 1980 Mar 24;26(12):929-34. No abstract available.

PMID:
6771478
11.

Differential effects on brain catecholamines by debrisoquin.

Maas JW, Hattox SE, Landis DH.

Biochem Pharmacol. 1979 Oct 15;28(20):3153-6. No abstract available.

PMID:
117812
12.

3-Methoxy-4-hydroxyphenethyleneglycol production by human brain in vivo.

Maas JW, Hattox SE, Greene NM, Landis DH.

Science. 1979 Sep 7;205(4410):1025-7.

PMID:
472724
13.
14.

A direct method for determining dopamine synthesis and output of dopamine metabolites from brain in awake animals.

Maas JW, Hattox SE, Martin DM, Landis DH.

J Neurochem. 1979 Mar;32(3):839-43. No abstract available.

PMID:
107275
15.
16.

Application and evaluation of limited mass monitoring with a gas chromatograph mass spectrometer computer system.

Murphy RC, Hattox SE, Helbig HR.

Biomed Mass Spectrom. 1978 Jul;5(7):444-52.

PMID:
678615
17.
18.

3-Methoxy-4-hydroxyphenethyleneglycol increase in plasma after stimulation of the nucleus locus coeruleus.

Crawley JN, Hattox SE, Maas JW, Roth RH.

Brain Res. 1978 Feb 10;141(2):380-4. No abstract available.

PMID:
626910
19.

Regional distribution of dopamine metabolites in human and primate brain.

Bacopoulos NG, Maas JW, Hattox SE, Roth RH.

Commun Psychopharmacol. 1978;2(4):281-6. No abstract available.

PMID:
103676
20.

A direct method for studying 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) production by brain in awake animals.

Maas JW, Hattox SE, Landis DH, Roth RH.

Eur J Pharmacol. 1977 Dec 1;46(3):221-8.

PMID:
412681
21.

Effects of nigrostriatal pathway stimulation and tropolone on plasma concentration of 3,4-dihydroxyphenylacetic acid.

Bacopoulos NG, Hattox SE, Roth RH.

Biochem Pharmacol. 1977 Nov 15;26(22):2197-9. No abstract available.

PMID:
588304
22.

The determination of a brain arteriovenous difference for 3-methoxy-4-hydroxyphenethyleneglycol (MHPG).

Maas JW, Hattox SE, Landis DH, Roth RH.

Brain Res. 1976 Dec 10;118(1):167-73. No abstract available.

PMID:
825199
23.

The separation and identification of dopamine 3-O-sulfate and dopamine 4-O-sulfate in urine of Parkinsonian patients.

Bronaugh RL, Hattox SE, Hoehn MM, Murphy RC, Rutledge CO.

J Pharmacol Exp Ther. 1975 Dec;195(3):441-52.

PMID:
1195131
24.

Structure-retention relationships in the gas chromatography of nucleosides.

Hattox SE, McCloskey JA.

Anal Chem. 1974 Sep;46(11):1378-83. No abstract available.

PMID:
4415921
25.

Characterization of cytosine nucleosides by mass spectrometry.

Liehr JG, von Minden DL, Hattox SE, McCloskey JA.

Biomed Mass Spectrom. 1974 Aug;1(4):281-5. No abstract available.

PMID:
4441623

Supplemental Content

Loading ...
Support Center